Therefore, new strategies are being pursued in AD therapy to selectively activate M1-AChR, through the development of highly selective agonists for M1R or the use of positive allosteric modulators, which selectively enhance the affinity of the M1 receptor for acetylcholine.26,36. This evidence concerns the gene CHRM1 and Alzheimer disease.